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A collection of fusion biocatalysts has been generated that can be used for self-sufﬁcient oxygenations or
ketone reductions. These biocatalysts were created by fusing a Baeyer-Villiger monooxygenase (cyclo-
hexanone monooxygenase from Thermocrispum municipale: TmCHMO) or an alcohol dehydrogenase
(alcohol dehydrogenase from Lactobacillus brevis: LbADH) with three different cofactor regeneration
enzymes (formate dehydrogenase from Burkholderia stabilis: BsFDH; glucose dehydrogenase from Sul-
folobus tokodaii: StGDH, and phosphite dehydrogenase from Pseudomonas stutzeri: PsPTDH). Their
tolerance against various organic solvents, including a deep eutectic solvent, and their activity and
selectivity with a variety of substrates have been studied. Excellent conversions and enantioselectivities
were obtained, demonstrating that these engineered fusion enzymes can be used as biocatalysts for the
synthesis of (chiral) valuable compounds.
© 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Biocatalysis can be used to synthesize chiral building blocks,
such as monomers for polymer materials, and precursors for
pharmaceuticals [1e4]. Enzymes are very suitable for catalyzing
reactions with high enantioselectivity to obtain chiral products. For
instance, alcohol dehydrogenases (ADHs, EC 1.1.1.X) e also known
as carbonyl reductases or ketoreductases e depend on NAD(P)H to
catalyze the asymmetric reduction of ketones to either (R)- or (S)-
alcohols in excellent enantiomeric excess (ee) [5]. These enzymes,
among others, have been applied for syntheses of pharmaceutical
precursors [2,4]. Another group of redox enzymes that depend on
NAD(P)H are the Baeyer-Villiger monooxygenases (BVMOs) (EC
1.14.13.X). These FAD-containing enzymes can catalyze regio- and
enantioselective transformations of ketones to esters or lactones,
using dioxygen and NADPH. Interest in the application of BVMOsLtd. This is an open access article uhas grown, in particular for the transformation of substituted cyclic
ketones to chiral lactones, for branched polyesters [6e9]. Specif-
ically, the recent discovery of robust BVMOs, such as the thermo-
stable cyclohexanone monooxygenase from Thermocrispum
municipale (TmCHMO), has led to great interest for exploring these
monooxygenases for industrial applications, as most of the previ-
ously reported BVMOs were quite unstable [10].
Both ADHs and BVMOs rely on the cofactor NAD(P)H for catal-
ysis, which is too expensive to apply in stoichiometric amounts, and
therefore should be regenerated. There are a number of different
approaches to recycle NAD(P)H [5,11,12]. One approach is to apply
another enzyme which can use the oxidized NAD(P)þ and a sacri-
ﬁcial cheap cosubstrate to regenerate the reduced nicotinamide
cofactor: the so-called “coupled-enzyme” approach. Three
commonly used coenzyme regenerating enzymes are formate de-
hydrogenase (FDH), glucose dehydrogenase (GDH), and phosphite
dehydrogenase (PTDH), all using relatively cheap substrates [12].
Instead of producing and adding these enzymes separately, the
recycling enzyme can also be covalently fused to the NADPH-
dependent enzyme through enzyme engineering (Scheme 1). Innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Scheme 1. Representation of self-sufﬁcient ADHs and BVMOs, with either GDH, FDH
or PTDH as fusion partner to recycle the nicotinamide cofactor NADPH.
Table 1
Fusion constructs.
Enzyme Fusion N-terminal Linker C-terminal Mw (kDa)
F-B BsFDH SGSAAG TmCHMO 104
G-B StGDH SGSAAG TmCHMO 102
P-B PsPTDH SRSAAG TmCHMO 99
F-A BsFDH SGSAAG LbADH 71
G-A StGDH SGSAAG LbADH 69
P-A PsPTDH SGSAAG LbADH 65
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produced enabling conversion using merely one biocatalyst.
Moreover, some studies on enzyme fusions provided evidence that
tethering of two enzymes can improve the productivity of a multi-
enzyme system [13]. In 2008 Torres Pazmi~no et al. developed a
platform for expressing BVMOs fused to PTDH for efﬁcient cofactor
regeneration [14,15]. Later, a few other studies reported enzyme
fusions with FDH [16], GDH [17], or PTDH [18e20], though no study
yet has compared a single biocatalyst with different regenerating
enzymes.
The aim of this work is to explore different recycling enzymes as
fusion partner for two oxidoreductase enzymes (BVMO and ADH),
and to compare their strengths and weaknesses for biocatalytic
applications. We fused three different regenerating enzymes to a
BVMO (TmCHMO, from Thermocrispum municipale) [10] and an (R)-
selective alcohol dehydrogenase (LbADH, from Lactobacillus brevis)
[21e23], to generate a panel of self-sufﬁcient biocatalysts. The
three recycling enzymes are: FDH from Burkholderia stabilis
(BsFDH) [24], GDH from Sulfolobus tokodaii (StGDH) [25], and an
engineered PTDH from Pseudomonas stutzeri (PsPTDH) [26,27]. The
fused enzymes were produced and puriﬁed, and applied for bio-
transformations. Both enzymes act on ketone substrates to form
interesting products, though many of such organic substrates have
low solubility in water. Therefore, the enzyme fusions were tested
with a wide range of solvents. In particular, the tolerance of these
biocatalysts to deep-eutectic solvents (DES) was evaluated, which
at present has not been studied to a great extent.2. Results and discussion
2.1. Cloning, expression and puriﬁcation
The cloning approach was similar to that of previous fusion
cloning work [14,15]. As linker region a variation of the short-linker
from previous work was used, which was found to be optimal for
fusionswith BVMOs [15]. For ease of denoting, TmCHMO is named B
(BVMO) while the LbADH is named A (ADH), see Table 1. The
cofactor regeneration enzymes are also denoted in single letter
codes: F for FDH, G for GDH and P for PTDH. After cloning of the six
constructs (Table 1), the plasmids were used to transform compe-
tent E. coli NEB 10b cells. These cells were then used for recombi-
nant expression and subsequent enzyme puriﬁcation. Only one of
the six fusion constructs had an inadequate level of soluble
expression: G-A. Although it was used for some of the initialexperiments, in later experiments this fusion enzyme was omitted.
The other fusion enzymes could be produced in high quantities
(>50mg/L culture). After lysis of the cells and protein puriﬁcation
through afﬁnity column chromatography, the enzyme fusions were
used for further testing and biotransformations.
2.2. Reaction optimization
The ﬁrst step was to establish optimal reaction conditions. The
reactions were set up using cyclohexanone (5mM) as model sub-
strate for the TmCHMO constructs, and acetophenone (5mM) for
the LbADH constructs (see Supporting Information, Section 2.1).
The optimal reaction conditions for each biocatalyst system were
similar. All fusions were able to fully convert the substrate under
mild reaction conditions: phosphate buffer 100mM pH 8.5 for
TmCHMO fusions, and phosphate buffer 100mM pH 7.5 for LbADH
constructs, at 30 C in most cases. Previous studies have shown that
PTDH is not inhibited by phosphate buffer [28]. The only exception
was G-B that afforded a better selectivity towards the formation of
caprolactone at 24 C, since at 30 C a signiﬁcant amount of cyclo-
hexanol was observed due to the undesired activity of StGDH with
cyclohexanone.
The biotransformations were monitored over time (Fig. 1). The
reactions catalyzed by BsFDH and PsPTDH constructs were mostly
completed after 16 h, while the StGDH fusions needed 24 h to
achieve full conversions. The conversion with the TmCHMO fusions
resulted in a linear increase of product in time, whereas the LbADH
fusions showed a higher initial rate up to 70% conversion, and then
it decreased until full conversion. This was probably due to the
relatively high KM value for acetophenone (2.8mM) of LbADH and/
or product inhibition.
Assuming that the TmCHMO and LbADH enzymes had roughly
the same catalytic properties (activity and KM) for the three
different fusions, the only difference concerning the kinetic per-
formance of the fusion enzymes is due to the recycling enzyme. The
amount of sacriﬁcial substrate (10mM glucose, 50mM sodium
formate or 20mM sodium phosphite) was decided based on the
reported KM values of each enzyme, ensuring maximal activity
(Vmax) throughout the whole reaction. The kcat values for the three
recycling enzymes PTDH, FDH and GDH with NADPþ are, respec-
tively: 6.5 s1 (at 25 C) [15], 4.75 s1 (at 30 C) [24], and ~3.8 s1 (at
35 C, derived from reported activity and temperature optimum)
[25]. This was in agreement with the time course of the bio-
transformations (Fig. 1): PTDH fusions were the fastest, while FDH
fusions were the second. From this initial experiment it was clear
that GDH constructs had the weakest performance. The respective
biotransformationswere the slowest, maybe due to the fact that the
reaction with G-B worked better at 24 C while the StGDH has a
relatively high temperature optimum. Furthermore, G-A showed
also a poor expression.
2.3. Enzymatic preparations
The need for NADPH is a cost factor when considering the
Fig. 1. Monitoring of the conversions in the self-sufﬁcient TmCHMO and LbADH-catalyzed enzymatic biotransformations.
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Pazmi~no et al. published interesting results using cell-free extract
preparations of different self-sufﬁcient BVMOs without external
addition of the nicotinamide cofactor [14]. This approach was also
tested for our fusions (Table 2, entries 1, 4, 7, 10, 13 and 16), but
resulted in good results only for G-B and P-B fusions. F-B and LbADH
fusions had a signiﬁcantly lower activity. Apart from that, and still
in order to make the process economically feasible, each
biotransformation using the puriﬁed enzyme was set up addingTable 2
Biotransformations mediated by self-sufﬁcient TmCHMOs and LbADHs using
different enzymatic preparations and different amounts of cofactor.
Entry Fusion Protein preparation [NADPH] (mM) Conv. (%)b ee (%)b,c
1 G-B Cell-free extracta e 92 e
2 G-B Puriﬁed 1 >99 e
3 G-B Puriﬁed 0.5 96 e
4 F-B Cell-free extracta e 10 e
5 F-B Puriﬁed 1 >99 e
6 F-B Puriﬁed 0.5 99 e
7 P-B Cell-free extracta e >99 e
8 P-B Puriﬁed 1 >99 e
9 P-B Puriﬁed 0.5 96 e
10 G-A Cell-free extracta e 13 81 (R)
11 G-A Puriﬁed 1 >99 >99 (R)
12 G-A Puriﬁed 0.5 n.d. n.d.
13 F-A Cell-free extracta e 68 96 (R)
14 F-A Puriﬁed 1 >99 >99 (R)
15 F-A Puriﬁed 0.5 74 >99 (R)
16 P-A Cell-free extracta e 42 >99 (R)
17 P-A Puriﬁed 1 >99 >99 (R)
18 P-A Puriﬁed 0.5 86 >99 (R)
a Cell-free extract preparations were prepared as described in the Experimental
Section.
b Measured by GC analysis.
c Caprolactone is not an optically active molecule so no ee value is associated to
TmCHMO constructs results. For the reactions with the puriﬁed enzyme, 2 mM of
TmCHMO fusion or 0.2mg/mL (approx. 2.5 mM) of LbADH fusion were used.just 0.5mM NADPH (Table 2, entries 3, 6, 9, 15 and 18). High con-
versions and excellent ee values were found, though the reactions
with LbADH (entries 15 and 18) could not reach full conversion.
Although the KM value for NADPH is 40 mM for the native LbADH,
possibly the KM of the respective fusion enzymes is a bit higher, as
was observed for other PTDH-BVMO fusions [14]. This could slow
down the reaction, in particular in combination with the afore-
mentioned slower reaction rates after 70% conversion, due to the
high KM for acetophenone (Fig. 1).2.4. Cosolvent screening
At this point, the model reaction for each fusion was fully
studied. However, in order to perform reactions with high substrate
concentrations, the low water solubility of many ketone substrates
must be addressed. One of the common strategies is the employ-
ment of an organic cosolvent. For this reason, the enzyme fusions
were ﬁrst tested with a wide range of organic solvents (1% v/v,
Fig. 2), including tert-butyl methyl ether (MTBE), methanol
(MeOH), ethanol (EtOH), 1,4-dioxane and acetonitrile (MeCN). First
of all, it must be pointed out that not a single cosolvent affected the
selectivity of LbADH fusion enzymes (data not shown), thus
providing the enantiopure (R)-alcohol. MTBE and acetonitrile
revealed to be the best cosolvents for all enzyme fusions, as they led
to high conversions (>90%) in all cases. Methanol and ethanol
showed very good results with most of the constructs, with the
exception of P-B using MeOH and G-A using EtOH; in these cases
the conversion values dropped down to 51% and 69%, respectively.
Finally, 1,4-dioxane caused a huge drop of activity (90% decrease)
with G-B and F-B fusions, and a 40% decrease for G-A.
These results are surprising, as it seems that particular combi-
nations of enzymes can be sensitive to a cosolvent, even though
other combinations containing one of those enzymes are tolerant.
For instance, with 1,4-dioxane and F-B, it is not simply that
TmCHMO was intolerant, since P-B did give full conversion. The
same was true for BsFDH, as F-A was able to afford 90% conversion.
Based on those two results, one would expect F-B to give high
conversion as well, yet it was only 10%. In other words, it was
observed that particular combinations of enzymes can be more
tolerant to organic solvents than other combinations with the same
enzyme. It could be that certain enzymes can transmit tolerance for
Fig. 2. Biotransformation of model substrates using different organic cosolvents (1% v/v).
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in P-B for 1,4-dioxane.
Taking all these data into account, we decided to test the fusions
behavior in a biphasic system using larger amounts of MTBE, as it
was the best cosolvent among the tested ones (see Supporting in-
formation, Section 2.2). The TmCHMO fusions were able to catalyze
the Baeyer-Villiger oxidation of cyclohexanone with full conversion
using up to 10% v/v of MTBE. An amount of 15% v/v of MTBE led to
full conversion using BsFDH and PsPTDH constructs, but caused a
drop in the StGDH fusion activity, indicating again that this fusion
was less stable. On the other hand, F-A was capable to convert
acetophenone into (R)-1-phenylethanol using up to 40% v/v of
MTBE, while P-A showed a small drop of activity at 20% v/v ofMTBE.
Overall, it was clear that for this cosolvent BsFDH was the most
tolerant NADPH-regenerating enzyme.
Deep eutectic solvents (DES) represent a promising new gen-
eration of environmentally-friendly solvents [29].We evaluated the
use of DES as cosolvents for the biotransformations catalyzed by the
engineered fusion biocatalysts. Concentrations of 10%e30% v/v of
DES derived from choline chloride and glycerol (ChCl:Gly 1:2mol/
mol) were employed (see Supporting information, Section 2.3). G-B
and F-B appeared as the most robust enzymes as they could achieve
full conversion to caprolactone using up to 20% v/v of DES. Besides,
F-A showed better results than P-A. As with the results with MTBE,
BsFDH was the most tolerant cofactor regenerating enzyme in non-
conventional media. Furthermore, a glucose-based DES (ChCl:glu-
cose at 1.5:1mol/mol) was tested both as cosolvent and cosubstrate
for producing caprolactone by G-B (see Supporting information,
Section 2.4). The corresponding results are very interesting as the
biotransformation (without adding external glucose) led to full
conversions.2.5. Substrate screening
In order to check the synthetic versatility of the engineered
fusion biocatalysts, other substrates were tested (see Fig. 3).
TmCHMO constructs were employed to catalyze the Baeyer-Villiger
oxidation of substrates differing on the ring substitution and the
ring size (substrates 2-4a, Table 3). In this manner, 4-
methylcyclohexanone (2a) was converted into (S)-4-methyl-3-caprolactone (S-2b) in full conversion and excellent enantiose-
lectivity (Table 3, entries 4e6). Cyclopentanone (3a) and cyclo-
butanone (4a) were also tested as substrates, but unfortunately
they were not converted at all (Table 3, entries 7e12). This was
quite surprising, as the native TmCHMO has been reported to be
active with both substrates [10]. The only reported difference
compared to substrate 1a was that 3a and 4a showed some sub-
strate inhibition. Perhaps the fusion gives an even stronger sub-
strate inhibition, or somehow the active site is slightly altered
through having a fusion partner, disabling TmCHMO to accept 3a or
4a.
Looking for a further exploitation of these enzyme fusions, thi-
oanisole (5a) was tested as substrate (Table 3, entries 13e15).
Mixtures of enantiopure methyl phenyl sulfoxide (5b) and the
corresponding sulfone (5c) were obtained, as was observed in a
recent study using another robust BVMO [30]. A time-point study
performedwith the G-B conﬁrmed the early formation of 5b and its
subsequent oxidation to 5c (see Supporting Information, Section
2.5).
Keeping in mind previous studies on ketone reductions with
ADHs [23], some acetophenone derivatives were chosen as alter-
native substrates for the LbADH fusions (substrates 7e12a, Table 3).
The lengthening of chain R2 from a methyl group (acetophenone,
6a; Table 3, entries 16 and 17) to an ethyl group (propiophenone,
7a; Table 3, entries 18 and 19) caused a loss of activity, although the
stereoselectivity remained perfect. As expected [23], when bio-
reductions were set up using butyrophenone (8a; Table 3, entries
20 and 21) or 2-methoxy-1-phenylethanone (9a; Table 3, entries 22
and 23) as substrates, a dramatic loss of activity was observed. At
this point, we decided to evaluate the inﬂuence of the aromatic
pattern substitution at different positions. For this purpose, we
studied various chlorine-substituted acetophenone derivatives
(10e12a). BsFDH fusion behaved reasonably well with p-chlor-
oacetophenone (10a; Table 3, entry 24) andm-chloroacetophenone
(11a; Table 3, entry 26) as substrates. On the contrary, although
PsPTDH construct maintained excellent selectivity, it afforded low
conversions for the same substrates (Table 3, entries 25 and 27).
Finally, the biotransformation of o-chloroacetophenone (12a)
catalyzed by the BsFDH fusion was set up leading to low conver-
sions (Table 3, entry 28).
Fig. 3. Panel of substrates studied in this work. Substrate 5a for TmCHMO can be oxidized to methyl phenyl sulfoxide (5b) or to (methylsulfonyl)benzene (5c).
Table 3
Substrate scope of the engineered self-sufﬁcient TmCHMO and LbADH fusion biocatalysts.
Entry Fusion Substrate Conv. (%)a ee (%)a,b
1 G-B 1a >99 e
2 F-B 1a >99 e
3 P-B 1a >99 e
4 G-B 2a >99 >99 (S)
5 F-B 2a >99 >99 (S)
6 P-B 2a >99 >99 (S)
7 G-B 3a <1 e
8 F-B 3a <1 e
9 P-B 3a <1 e
10 G-B 4a <1 e
11 F-B 4a <1 e
12 P-B 4a <1 e
13 G-B 5a 75% 5b þ 21% 5c >99 [(R)-5b]
14 F-B 5a 26% 5b þ 74% 5c >99 [(R)-5b]
15 P-B 5a 51% 5b þ 47% 5c >99 [(R)-5b]
16 F-A 6a >99 >99 (R)
17 P-A 6a >99 >99 (R)
18 F-A 7a 85 >99 (R)
19 P-A 7a 55 >99 (R)
20 F-A 8a <1 n.d.
21 P-A 8a <1 n.d.
22 F-A 9a 10 >99 (S)c
23 P-A 9a 2 n.d.
24 F-A 10a 90 >99 (R)
25 P-A 10a 10 >99 (R)
26 F-A 11a 88 >99 (R)
27 P-A 11a 15 >99 (R)
28 F-A 12a 16 >99 (R)
a Determined by GC analysis.
b Enantiomeric excess values of product 5b were determined by chiral HPLC analysis.
c Change in Cahn-Ingold-Prelog priority. n.d. not determined.
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At this point, we aimed to show the applicability of the enzyme
fusions by scaling-up some selected biotransformations. Before
that, the effect of the substrate concentration and the amount of
biocatalyst were studied (Supporting information, Section 2.6) in
order to identify the best conditions for each preparation. Once
optimized, several semi-preparative biotransformations were set
up using the best conditions for each fusion without observing the
formation of any by-product. Hence, for P-B 25mg of cyclohexa-
none (10mM) were transformed into caprolactone at pH 8.5 with
full conversion but in moderate isolated yield (51%) afterpuriﬁcation by extraction and centrifugation of the combined
organic phases. Suspecting that part of the caprolactone had been
hydrolyzed, the biotransformation was set up using a phosphate
buffer pH 7.5. In this case, it was possible to obtain the caprolactone
in high isolated yield (90%). Afterwards, the same Baeyer-Villiger
oxidation were performed using F-B and G-B. Again, full conver-
sions and high isolated yields (89% and 80%, respectively) were
attained for caprolactone after an extraction protocol. The LbADH
constructs were also tested in semi-preparative bio-
transformations. However, F-A revealed worse results than those
obtained at small scale. Using 15mg of acetophenone (20mM), it
was transformed into (R)-1-phenylethanol in 65% conversion. After
A. Mourelle-Insua et al. / Tetrahedron 75 (2019) 1832e1839 1837separation of the remaining ketone, the desired enantiopure
alcohol was obtained in 51% isolated yield. On the other hand, the
result obtained in the same bioreduction catalyzed by P-A was as
good as that obtained at small scale, and the corresponding alcohol
was produced in full conversion, with excellent enantioselectivity
and high isolated yield (85%).
3. Conclusions
In this study we have developed and investigated three NADPH-
regenerating fusion partners with two different enzyme systems: a
BVMO and an ADH. With the exception of one fusion construct
(StGDH with LbADH), all fusion enzymes resulted in good soluble
expression as well as fully functional as self-sufﬁcient biocatalysts.
The fusion biocatalysts displayed tolerance to various organic
cosolvents, including DES. From the different fusion partners, FDH
was the most tolerant to organic solvents, fully converting cyclo-
hexanone for the BVMO fusion at 15% v/v MTBE, and acetophenone
for the ADH fusion even at 40% v/v MTBE.We also demonstrate that
the fusion enzymes can be used as enantioselective biocatalysts for
a large variety of reactions by retaining almost all catalytic char-
acteristics of the native non-fused enzymes. We demonstrated the
applicability of three different NADPH regenerating fusions for
these two enzyme systems, which broadens the choice of regen-
erating enzymes for future applications of these systems.
4. Experimental section
4.1. General materials and methods
Oligonucleotide primers were ordered from Sigma-Aldrich
(Merck KGaA, Darmstadt, Germany). T4 ligase and restriction
enzyme BsaI were ordered from New England Biolabs. The PfuUltra
Hotstart PCR master mix was purchased from Agilent Technologies.
Escherichia coli NEB® 10-beta (New England Biolabs) chemically
competent cells were used as host for cloning of the recombinant
plasmids, and as host for protein expression.
All acetophenones, cyclohexanones, cyplopentanone, cyclo-
butanone and thioanisole were purchased from Sigma-Aldrich-
Fluka. NADPH as enzyme cofactor and all the other chemical re-
agents were obtained with the highest quality available from
Sigma-Aldrich-Fluka (Steinheim, Germany).
NMR spectra were recorded on a Bruker AV300 MHz spec-
trometer (Bruker Co., Faellanden, Switzerland). All chemical shifts
(d) are given in parts per million (ppm) and referenced to the re-
sidual solvent signal as internal standard.
Gas chromatography (GC) and high performance liquid chro-
matography (HPLC) analyses were performed for conversion and
enantiomeric excess measurements. GC analyses were performed
on an Agilent HP6820 GC chromatograph equipped with a FID
detector. HPLC analyses were carried out in a Hewlett Packard 1100
chromatograph UV detector at 210 nm. Formore details, see Section
1 in the Supporting Information. Thin-layer chromatography (TLC)
was conducted with Merck Silica Gel 60 F254 precoated plates and
visualized with UV and potassium permanganate stain. Column
chromatography was performed using Merck Silica Gel 60
(230e400 mesh).
4.2. Cloning and puriﬁcation
Cloning of fusion constructs: Three fusion constructs with the
lbadh gene were cloned into a pBAD vector through the Golden
Gate method. The pBAD vector contains a region coding for an N-
terminal His-tag (6xHis) upstream from the ﬁrst BsaI restriction
site, an AraC promoter, and an ampicillin-resistance gene (bla).Primers were designed to have a non-overlapping region coding for
the BsaI restriction site (GGTCTCNNNNNN), such that the vector
and PCR product have a four base-pair overlap after digestion with
BsaI. These primers were used for PCR to amplify the lbadh gene
(accession: Q84EX5) from an in-house plasmid, fdh (accession:
EU825923.1) and gdh (accession: Q96ZY7) synthetic codon-
optimized genes were ordered from Genscipt (NJ, USA), and ptdh
x12 mutant was also cloned from an in-house plasmid. Primers
were designed such that the lbadhwould be the second gene of the
fusion; at the C-terminal side of the fusion enzyme. In addition to
the BsaI sites, an additional ‘linker’ region was added to the reverse
primers of the ﬁrst gene and the forward primer of the second gene
of a construct. These introduced ‘linker’ regions together code for a
short peptide linker (SGSAAG), after ligation of the PCR products.
The fusion constructs were produced by incubating together:
two PCR products (lbadh gene and either fdh, gdh or ptdh), pBAD
vector containing BsaI sites, BsaI restriction enzyme, T4 ligase,
ligation buffer, and sterile miliQ water (total volume of 20 mL). The
incubation temperature alternated between 16 C (for 5min) and
37 C (for 10min) for 30 cycles, thenwas set to 55 C for 10min, and
ﬁnally to 80 C for 20min to inactivate the enzymes. To transform
host cells with the fusion constructs, 3 mL of the Golden Gate re-
action was added to chemically competent E. coli cells, and a heat
shock was applied at 42 C for 30 s. After overnight growth on a
lysogeny broth (LB) agar plate with ampicillin, colonies were
picked, grown in liquid LB with appropriate antibiotic, and the
plasmidswere isolated and sent for sequencing (GATC, Germany) to
conﬁrm correct ligation of the genes. For the three constructs with
TmCHMO, traditional restriction-digestion cloning was used.
All enzymes were expressed using NEB 10-b Escherichia coli
cells. The freshly-prepared strains were cultivated in TB medium
supplemented with 50 mg/mL ampicillin at 37 C. Protein expres-
sion was induced by adding ʟ-arabinose (0.02% w/v) when A600
reached 0.5. G-B and F-Bwere incubated overnight at 30 C, P-A and
P-B were incubated at 24 C for 48 h and G-A and F-A were incu-
bated at 17 C for 72 h. After this time, the cells were harvested by
centrifugation.
The cells were resuspended in 20mM phosphate buffer pH 7.5
(TmCHMO fusions were implemented with FAD) and lysed in an
iced bath by ultrasonication (cycles of 20s on/20s off for 7min).
After centrifugation, the supernatant was used either for protein
puriﬁcation using Ni-sepharose material or as cell-free extract
preparations for biotransformations.
For lyophilization purposes, the cells obtained after expression
were resuspended in the minimum amount of 20mM phosphate
buffer pH 7.5 and lyophilized using an Alpha 2e4 DLplus freeze
dryer (Martin Christ Gefriertrocknungsanlagen GmbH, Germany).
4.3. Conversion of cyclohexanone and derivatives, cyclopentanone,
cyclobutanone and thioanisole using self-sufﬁcient TmCHMOs
Puriﬁed self-sufﬁcient TmCHMOs (2 mM or 4 mM) were
employed for biotransformation of cyclohexanone (5e25mM), 4-
methylcyclohexanone (5mM), cyclopentanone (5mM), cyclo-
butanone (5mM) and thioanisole (5mM) at 30 C (F-B and P-B) or
24 C (G-B) and 250 rpm. All reactions contained 1 or 0.5mmol
NADPH, the co-substrate (10mM glucose for G-B, 50mM sodium
formate for F-B and 20mM sodium phosphite for P-B) and 100mM
phosphate buffer pH 8.5. Additionally, G-B fusion needs the
external addition of magnesium chloride (1mM). In some cases, a
cosolvent (1% v/v 1,4-dioxane, 1% v/v acetonitrile, 1% v/v ethanol, 1%
v/v methanol, 1e50% v/v tert-butyl methyl ether) or ChCl:Gly
(1:2mol/mol) was added. In any case, the ﬁnal volume of the re-
action was adjusted up to 0.5mL in a 2mL eppendorf tube.
For cell-free extract biotransformations, 5mM cyclohexanone
A. Mourelle-Insua et al. / Tetrahedron 75 (2019) 1832e18391838was used as substrate and the reaction was implemented with the
corresponding co-substrate (10mMglucose for G-B, 50mM sodium
formate for F-B and 20mM sodium phosphite for P-B) and 1mM of
MgCl2$6H2O when G-B was employed. Cell-free extract prepara-
tions were used at 8mg/mL concentration and the ﬁnal volumewas
adjusted with 100mM phosphate buffer pH 8.5 up to a 0.5mL in a
2mL eppendorf tube. The reactions were incubated at 30 C (F-B
and P-B) or 24 C (G-B) and 250 rpm for 24 h.
When using lyophilized preparations (10mg), cyclohexanone
(5mM) was used as substrate and reactions were implemented
with NADPH (1mM), the corresponding co-substrate (10mM
glucose for G-B, 50mM sodium formate for F-B and 20mM sodium
phosphite for P-B) and 1mM of MgCl2$6H2O when G-B was
employed. The ﬁnal volume was adjusted up to 0.5mL with
100mM phosphate buffer pH 8.5 in a 2mL eppendorf tube and the
reactions were incubated at 30 C (F-B and P-B) or 24 C (G-B) and
250 rpm for 24 h.
After incubation, all reactions were extracted with ethyl acetate
(2 0.2mL) and the organic layers were combined and dried over
anhydrous Na2SO4. The results were analyzed using GC and/or
HPLC.
4.4. Preparative biotransformation of cyclohexanone into
caprolactone using TmCHMO fusions
G-B (2 mM) was employed to convert 30mg of cyclohexanone
(5mM) into caprolactone. The reaction media was composed of
100mM phosphate buffer pH 8.5 implemented with NADPH
(1mM), glucose (10mM) and MgCl2$6H2O (1mM). The reaction
was set up in a 50mL Falcon tube and incubated at 24 C and
250 rpm for 24 h. After this time, the mixture was extracted with
ethyl acetate (3 20mL), the organic layers separated by centri-
fugation (5min, 4900 rpm), combined and ﬁnally dried over
anhydrous Na2SO4. Conversion was determined by GC. Capro-
lactone was obtained in 80% isolated yield (>99% conv.).
F-B (4 mM)was used to convert 30mg of cyclohexanone (15mM)
into caprolactone in 100mM phosphate buffer pH 8.5 in a 50mL
Falcon tube. The reaction was implemented with NADPH (1mM)
and sodium formate (50mM) and incubated at 30 C for 24 h. Af-
terwards, the mixture was extracted with ethyl acetate (3 20mL),
the organic layers separated by centrifugation (5min, 4900 rpm),
combined and ﬁnally dried over anhydrous Na2SO4. Conversionwas
determined by GC. Caprolactone was obtained in 89% isolated yield
(>99% conv.).
P-B (2 mM) was employed to convert 30mg of cyclohexanone
(10mM) into caprolactone. The reactionmedia (100mMphosphate
buffer pH 7.5) was implemented with NADPH (1mM) and sodium
phosphite (20mM) and the reaction was incubated at 30 C for
24 h. After this time, the mixture was extracted with ethyl acetate
(3 20mL), the organic layers separated by centrifugation (5min,
4900 rpm), combined and ﬁnally dried over anhydrous Na2SO4.
Conversion was determined by GC. Caprolactone was obtained in
90% isolated yield (>99% conv.).
4.5. General procedures for conversion of acetophenone and
derivatives using self-sufﬁcient LbADHs
Puriﬁed self-sufﬁcient LbADHs (0.2mg/mL or 4mg/mL) were
employed for biotransformation of acetophenone (5e25mM) and
derivatives (5mM) at 30 C and 250 rpm. All reactions contained 1
or 0.5mmol NADPH, the co-substrate (10mM glucose for G-A,
50mM sodium formate for F-A and 20mM sodium phosphite for P-
A), MgCl2$6H2O (1mM) and 100mM phosphate buffer pH 7.5. In
some cases, a cosolvent (1% v/v 1,4-dioxane, 1% v/v acetonitrile, 1%
v/v ethanol, 1% v/v methanol, 1e50% v/v tert-butyl methyl ether),ChCl:Gly (1:2mol/mol) or ChCl:Glu (1.5:1mol/mol) was added. In
any case, the ﬁnal volume of the reactionwas adjusted up to 0.5mL
in a 1.5mL eppendorf tube.
For cell-free extract biotransformations, 5mM acetophenone
was used as substrate and the reaction was implemented with the
corresponding co-substrate (10mM glucose for G-A, 50mM so-
dium formate for F-A and 20mM sodium phosphite for P-A) and
MgCl2$6H2O (1mM). Cell-free extract preparations were used at
8mg/mL concentration and the ﬁnal volume was adjusted with
100mM phosphate buffer pH 7.5 up to a 0.5mL in a 1.5mL
eppendorf tube. The reactions were incubated at 30 C and 250 rpm
for 24 h.
When using lyophilized preparations (10mg), acetophenone
(5mM) was used as substrate and reactions were implemented
with NADPH (1mM), the corresponding co-substrate (10mM
glucose for G-A, 50mM sodium formate for F-A and 20mM sodium
phosphite for P-A) and MgCl2$6H2O (1mM). The ﬁnal volume was
adjusted up to 0.5mL with 100mM phosphate buffer pH 7.5 in a
1.5mL eppendorf tube and the reactions were incubated at 30 C
and 250 rpm for 24 h.
After incubation, all reactions were extracted with ethyl acetate
(2 0.2mL) and the organic layers were combined and dried over
anhydrous Na2SO4. The results were analyzed using GC and/or
HPLC.4.6. Preparative biotransformation of acetophenone into (R)-1-
phenylethanol using LbADH fusions
F-A (0.4mg/mL) was used to convert 30mg of acetophenone
(20mM) into (R)-1-phenylethanol. The reaction media contained
NADPH (1mM), sodium formate (50mM), MgCl2$6H2O (1mM) and
100mM phosphate buffer pH 7.5. This mixture was incubated at
30 C for 24 h and, afterwards, it was extracted with ethyl acetate
(3 20mL), the organic layers separated by centrifugation (5min,
4900 rpm), combined and ﬁnally dried over anhydrous Na2SO4.
Conversion and enantiomeric excess were determined by GC. (R)-1-
phenylethanol was obtained in 51% isolated yield (65% conv.) after
puriﬁcation by column chromatography (Hex: EtOAc 3:1).
P-A (0.2mg/mL) was employed to convert 30mg of acetophe-
none (10mM) into (R)-1-phenylethanol. The reaction media
(100mM phosphate buffer pH 8.5) was implemented with NADPH
(1mM), sodium phosphite (20mM) and MgCl2$6H2O (1mM) and
the reaction was incubated at 30 C for 24 h. After this time, the
mixture was extracted with ethyl acetate (3 20mL), the organic
layers separated by centrifugation (5min, 4900 rpm), combined
and ﬁnally dried over anhydrous Na2SO4. Conversion and enan-
tiomeric excess were determined by GC. (R)-1-phenylethanol was
obtained in 85% isolated yield (>99% conv.).Acknowledgements
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